Ocuphire Pharma Results Presentation Deck
Ocuphire Pharma
Nasdaq: OCUP
Upcoming Catalysts:
✓ Topline Results APX3330 ZETA-1
P2b trial for DR/DME (Early 2023)
EOP2 FDA Meeting for APX3330
(2H 2023)
Pivotal Phase 3 Trials for Nyxol in
Presbyopia with 1st Data
Readouts (Late 2023)
Potential Approval of 1st Nyxol
NDA (Late 2023)
Stock Price¹
Market Cap¹
Cash (Pro-Forma)2,3
Shares Outstanding²
Average Daily Volume
Cash Runway Into 2025
$3.67
$77M
-$49 M
20.8M
~200k Shares
¹ As of close on January 24, 2023; 2 End of 3Q22 (10-Q);
3 Includes upfront payment from License Agreement
Corporate Highlights
Two Lead Clinical-Stage Novel Drugs Addressing Multiple Large
Ophthalmology Markets (~$20B US total) with Limited to No Competition
& Patent Coverage to 2034+
APX3330 oral tablets
Diabetic Retinopathy/Diabetic
Macular Edema (DR/DME) -
diabetic eye disease
Nyxol preservative-free eyedrops
Reversal of Mydriasis (RM) - eye dilation
Presbyopia (P) - age-related blurry near vision
Night Vision Disturbances (NVD) – halos, glares, starbursts
Successful Execution of 5 Trials in Last 2 Years with 6 Positive Phase 3 &
Phase 2 Data Read-outs for Nyxol in RM, Presbyopia, and NVD
NDA submitted Nov 2022 for Nyxol's first indication in RM
Global License Agreement Signed in Late 2022 with Viatris to Develop and
Commercialize Nyxol for All Indications in the US and Globally
Strong Financial Position (with No Debt) to Support Operations into 2025
and Coverage from 5 Biotech Research Analysts
Ocuphire
PHARMAView entire presentation